MX2016002903A - Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah. - Google Patents

Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.

Info

Publication number
MX2016002903A
MX2016002903A MX2016002903A MX2016002903A MX2016002903A MX 2016002903 A MX2016002903 A MX 2016002903A MX 2016002903 A MX2016002903 A MX 2016002903A MX 2016002903 A MX2016002903 A MX 2016002903A MX 2016002903 A MX2016002903 A MX 2016002903A
Authority
MX
Mexico
Prior art keywords
hendra
immunogenic compositions
nipah virus
virus
glycoprotein
Prior art date
Application number
MX2016002903A
Other languages
English (en)
Inventor
John M Hardham
Paul J Dominowski
jin-an Huang
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MX2016002903A publication Critical patent/MX2016002903A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18211—Henipavirus, e.g. hendra virus
    • C12N2760/18222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18211—Henipavirus, e.g. hendra virus
    • C12N2760/18233—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18211—Henipavirus, e.g. hendra virus
    • C12N2760/18234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Abstract

Esta invención se refiere a composiciones inmunógenas de los virus Hendra y Nipah y procedimientos de uso; la invención se refiere adicionalmente a composiciones inmunógenas que comprenden glicoproteína G del virus Hendra y procedimientos de protección frente a infección o enfermedad por el virus Nipah; la invención también se refiere a procedimientos para distinguir sujetos vacunados con las composiciones inmunógenas de la invención de los infectados con los virus Hendra y/o Nipah.
MX2016002903A 2013-09-05 2014-09-03 Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah. MX2016002903A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361874085P 2013-09-05 2013-09-05
PCT/US2014/053871 WO2015034903A1 (en) 2013-09-05 2014-09-03 Hendra and nipah virus g glycoprotein immunogenic compositions

Publications (1)

Publication Number Publication Date
MX2016002903A true MX2016002903A (es) 2016-06-06

Family

ID=51539385

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002903A MX2016002903A (es) 2013-09-05 2014-09-03 Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.

Country Status (6)

Country Link
US (2) US20160199482A1 (es)
CN (2) CN105530956A (es)
AU (1) AU2014315353A1 (es)
HK (1) HK1224177A1 (es)
MX (1) MX2016002903A (es)
WO (1) WO2015034903A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ733383A (en) * 2013-09-19 2022-12-23 Zoetis Services Llc Oil-based adjuvants
EP3082856A1 (en) * 2013-12-16 2016-10-26 Zoetis Services LLC Hendra and nipah virus g glycoprotein immunogenic compositions
CN108624602B (zh) * 2017-03-24 2020-10-16 华中农业大学 一株具有阻断活性的抗尼帕病毒g蛋白的单克隆抗体及其应用
US20210008195A1 (en) * 2017-12-20 2021-01-14 Zoetis Services Llc Vaccines against hendra and nipah virus infection
CN113391067B (zh) * 2021-06-16 2023-07-25 军事科学院军事医学研究院军事兽医研究所 抗尼帕病毒g蛋白抗体的间接elisa检测方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002309476A1 (en) * 2001-01-10 2002-10-08 The Texas A And M University System Method of preventing t-cell mediated responses by map proteins
ME00491B (me) * 2001-07-27 2011-10-10 Zoetis Services Llc Vakcina protiv bolesti zapadnog nila
PT2495252T (pt) * 2004-07-09 2018-06-22 Henry M Jackson Found Advancement Military Medicine Inc Formas solúveis de glicoproteína g de vírus hendra e de vírus nipah
MX2010005014A (es) * 2007-11-06 2010-06-30 Wyeth Llc Vacuna viva avirulenta de mycoplasma hyopneumoniae con adyuvante.
CN104001170B (zh) * 2008-06-27 2016-08-24 硕腾有限责任公司 新颖的佐剂组合物
CN110680913A (zh) * 2011-05-13 2020-01-14 硕腾有限公司 亨德拉和尼帕病毒g糖蛋白免疫原性组合物
EP3082856A1 (en) * 2013-12-16 2016-10-26 Zoetis Services LLC Hendra and nipah virus g glycoprotein immunogenic compositions

Also Published As

Publication number Publication date
US20160199482A1 (en) 2016-07-14
WO2015034903A1 (en) 2015-03-12
US20190083604A1 (en) 2019-03-21
HK1224177A1 (zh) 2017-08-18
AU2014315353A1 (en) 2016-03-10
CN109078179A (zh) 2018-12-25
CN105530956A (zh) 2016-04-27

Similar Documents

Publication Publication Date Title
MX352604B (es) Composiciones inmunogenicas de la glucoproteina g de los virus hendra y nipah.
MX2022013524A (es) Anticuerpos neutralizantes para el virus de inmunodeficiencia humana.
PH12017500207A1 (en) Indoles for use in influenza virus infection
PH12015502377A1 (en) Stabilized soluble pre-fusion rsv f polypeptides
PH12015502735A1 (en) Stabilized soluble pre-fusion rsv f polypeptides
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
PH12016500960A1 (en) Hendra and nipah virus g glycoprotein immunogenic compositions
MY168959A (en) Vaccine compositions for the prevention of dengue virus infection
MX2015000446A (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue.
MX2016002903A (es) Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.
EP3212658A4 (en) 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
IL265833A (en) Novel hla hpv16 unrestricted t-cell compositions, compositions and methods for their use
PH12016500465A1 (en) Deoxynojirimycin derivatives and methods of their using
EA201790517A1 (ru) Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
WO2015054678A3 (en) Human papilloma virus therapeutic vaccine
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
PH12017501943B1 (en) Influenza virus neutralizing peptidomimetic compounds
MX2016004961A (es) Procedimientos y composiciones para el tratamiento de infecciones por s. equi.
EA201390452A1 (ru) Вакцина
EA201992167A1 (ru) Вакцина
PH12015502304A1 (en) Use of pidotimod to treat irritable bowel syndrome
TH1601001245A (th) ไวรัสโรคมาเร็กชนิดรีคอมบิแนนต์และการใช้ดังกล่าว